Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

Inclusion criteria

• Individuals aged ≥ 18 years but < 70 years
• Male or female
• Body mass index of over 18 kg/m2 and < 35 kg/m2

Additional inclusion criteria for IH group

• Fasting plasma glucose <7.0 mmol/L and HbA1c < 6.5%
• 1 hour plasma glucose ≥8.6 and <11.6 mmol/L on 75g oral glucose tolerance test (OGTT)
• No use of glucose lowering drugs in past 6 months

Additional inclusion criteria for T2D group

• HbA1c 6.5 to 10% at screening
• On diet control, or stable dose of oral glucose lowering drugs metformin for at least 8 weeks

Exclusion criteria

• 1. Subjects who do not agree to participate in this study. 2. Country of birth is unknown. 3. Body weight less than 45kg. 4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).

• Subjects with severe renal dysfunction as defined by eGFR <30 ml/min/1.73m2 or patients receiving renal dialysis (such as haemodialysis or continuous ambulatory peritoneal dialysis).

• Severe hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times upper limit of normal.

• Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or history of myocardial infarction within last 12 months.

• History of drug abuse or excessive alcohol intake based on investigator judgment.

• Dehydration, diarrhoea or vomiting at the time of recruitment. 10. Subjects with severe infection, in perioperative period or with serious injury at the time of recruitment.

• Subjects with anaemia (Haemoglobin <9.0mg/dL). 12. Pregnant or lactating or intending to become pregnant within 30 days after last dose of study drug.

• Participation in a clinical trial with investigational product within 30 days before enrolment.

• Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥300 mL of blood within 30 days prior to study drug administration.

• Subjects judged unsuitable for the study based on investigator judgment. 16. Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued.

• Unwilling or unable to follow protocol requirements.